Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size was valued at US$ 11620 million in 2023. With growing demand in downstream market, the Human Immunodeficiency Virus (HIV)-1 Therapeutics is forecast to a readjusted size of US$ 12310 million by 2030 with a CAGR of 0.8% during review period.
The research report highlights the growth potential of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. Human Immunodeficiency Virus (HIV)-1 Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Immunodeficiency Virus (HIV)-1 Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
Key Features:
The report on Human Immunodeficiency Virus (HIV)-1 Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It may include historical data, market segmentation by Type (e.g., Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Human Immunodeficiency Virus (HIV)-1 Therapeutics industry. This include advancements in Human Immunodeficiency Virus (HIV)-1 Therapeutics technology, Human Immunodeficiency Virus (HIV)-1 Therapeutics new entrants, Human Immunodeficiency Virus (HIV)-1 Therapeutics new investment, and other innovations that are shaping the future of Human Immunodeficiency Virus (HIV)-1 Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Human Immunodeficiency Virus (HIV)-1 Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Immunodeficiency Virus (HIV)-1 Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Immunodeficiency Virus (HIV)-1 Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Market Segmentation:
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size was valued at US$ 11620 million in 2023. With growing demand in downstream market, the Human Immunodeficiency Virus (HIV)-1 Therapeutics is forecast to a readjusted size of US$ 12310 million by 2030 with a CAGR of 0.8% during review period.
The research report highlights the growth potential of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market. Human Immunodeficiency Virus (HIV)-1 Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Immunodeficiency Virus (HIV)-1 Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
Key Features:
The report on Human Immunodeficiency Virus (HIV)-1 Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It may include historical data, market segmentation by Type (e.g., Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Human Immunodeficiency Virus (HIV)-1 Therapeutics industry. This include advancements in Human Immunodeficiency Virus (HIV)-1 Therapeutics technology, Human Immunodeficiency Virus (HIV)-1 Therapeutics new entrants, Human Immunodeficiency Virus (HIV)-1 Therapeutics new investment, and other innovations that are shaping the future of Human Immunodeficiency Virus (HIV)-1 Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Human Immunodeficiency Virus (HIV)-1 Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Immunodeficiency Virus (HIV)-1 Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Immunodeficiency Virus (HIV)-1 Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
Market Segmentation:
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry and Fusion Inhibitors
- Protease Inhibitors (PIs)
- Integrase Inhibitors
- Coreceptor Antagonists
- Hospitals
- Clinics
- Labs
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie, Inc.(U.S.)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Boehringer Ingelheim GmbH (Germany)
- Genentech, Inc. (U.S.)
- Cipla, Inc. (India)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2030
2.1.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Type
2.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
2.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2.3 Entry and Fusion Inhibitors
2.2.4 Protease Inhibitors (PIs)
2.2.5 Integrase Inhibitors
2.2.6 Coreceptor Antagonists
2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
2.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Labs
2.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
2.5.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Players
3.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS BY REGIONS
4.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024)
5.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
5.3 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024)
6.2 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
6.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics by Country (2019-2024)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET FORECAST
10.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.4 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Region (2025-2030)
10.3.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.3 Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.5 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.6 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.2 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.3 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.4 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.3 Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.4 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.5 GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Type (2025-2030)
10.7 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 AbbVie, Inc.(U.S.)
11.1.1 AbbVie, Inc.(U.S.) Company Information
11.1.2 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 AbbVie, Inc.(U.S.) Main Business Overview
11.1.5 AbbVie, Inc.(U.S.) Latest Developments
11.2 Merck & Co., Inc. (U.S.)
11.2.1 Merck & Co., Inc. (U.S.) Company Information
11.2.2 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Merck & Co., Inc. (U.S.) Main Business Overview
11.2.5 Merck & Co., Inc. (U.S.) Latest Developments
11.3 Bristol-Myers Squibb Company (U.S.)
11.3.1 Bristol-Myers Squibb Company (U.S.) Company Information
11.3.2 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bristol-Myers Squibb Company (U.S.) Main Business Overview
11.3.5 Bristol-Myers Squibb Company (U.S.) Latest Developments
11.4 Boehringer Ingelheim GmbH (Germany)
11.4.1 Boehringer Ingelheim GmbH (Germany) Company Information
11.4.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Boehringer Ingelheim GmbH (Germany) Main Business Overview
11.4.5 Boehringer Ingelheim GmbH (Germany) Latest Developments
11.5 Genentech, Inc. (U.S.)
11.5.1 Genentech, Inc. (U.S.) Company Information
11.5.2 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Genentech, Inc. (U.S.) Main Business Overview
11.5.5 Genentech, Inc. (U.S.) Latest Developments
11.6 Cipla, Inc. (India)
11.6.1 Cipla, Inc. (India) Company Information
11.6.2 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Cipla, Inc. (India) Main Business Overview
11.6.5 Cipla, Inc. (India) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2030
2.1.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Type
2.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
2.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2.3 Entry and Fusion Inhibitors
2.2.4 Protease Inhibitors (PIs)
2.2.5 Integrase Inhibitors
2.2.6 Coreceptor Antagonists
2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type
2.3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Labs
2.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application
2.5.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Players
3.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS BY REGIONS
4.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024)
5.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
5.3 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024)
6.2 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
6.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics by Country (2019-2024)
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS MARKET FORECAST
10.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.1.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast
10.2 Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.2.4 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3 APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Region (2025-2030)
10.3.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.3 Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.5 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.3.6 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.2 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.3 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.4 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.4.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5 Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.3 Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.4 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.5.5 GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast
10.6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Type (2025-2030)
10.7 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 AbbVie, Inc.(U.S.)
11.1.1 AbbVie, Inc.(U.S.) Company Information
11.1.2 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 AbbVie, Inc.(U.S.) Main Business Overview
11.1.5 AbbVie, Inc.(U.S.) Latest Developments
11.2 Merck & Co., Inc. (U.S.)
11.2.1 Merck & Co., Inc. (U.S.) Company Information
11.2.2 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Merck & Co., Inc. (U.S.) Main Business Overview
11.2.5 Merck & Co., Inc. (U.S.) Latest Developments
11.3 Bristol-Myers Squibb Company (U.S.)
11.3.1 Bristol-Myers Squibb Company (U.S.) Company Information
11.3.2 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bristol-Myers Squibb Company (U.S.) Main Business Overview
11.3.5 Bristol-Myers Squibb Company (U.S.) Latest Developments
11.4 Boehringer Ingelheim GmbH (Germany)
11.4.1 Boehringer Ingelheim GmbH (Germany) Company Information
11.4.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Boehringer Ingelheim GmbH (Germany) Main Business Overview
11.4.5 Boehringer Ingelheim GmbH (Germany) Latest Developments
11.5 Genentech, Inc. (U.S.)
11.5.1 Genentech, Inc. (U.S.) Company Information
11.5.2 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Genentech, Inc. (U.S.) Main Business Overview
11.5.5 Genentech, Inc. (U.S.) Latest Developments
11.6 Cipla, Inc. (India)
11.6.1 Cipla, Inc. (India) Company Information
11.6.2 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Cipla, Inc. (India) Main Business Overview
11.6.5 Cipla, Inc. (India) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Table 3. Major Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Major Players of Entry and Fusion Inhibitors
Table 5. Major Players of Protease Inhibitors (PIs)
Table 6. Major Players of Integrase Inhibitors
Table 7. Major Players of Coreceptor Antagonists
Table 8. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 10. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 11. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 12. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Player (2019-2024)
Table 16. Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Products Offered
Table 17. Human Immunodeficiency Virus (HIV)-1 Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 21. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Regions (2019-2024)
Table 22. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 23. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 24. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 25. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country (2019-2024)
Table 26. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 27. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 28. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 29. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 30. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 31. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Table 32. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 33. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 34. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 35. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 36. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 37. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country (2019-2024)
Table 38. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 39. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 40. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 41. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 42. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Table 44. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 45. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 46. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 47. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 48. Key Market Drivers & Growth Opportunities of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 49. Key Market Challenges & Risks of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 50. Key Industry Trends of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 51. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 52. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 53. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 54. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 55. AbbVie, Inc.(U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 56. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 57. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 58. AbbVie, Inc.(U.S.) Main Business
Table 59. AbbVie, Inc.(U.S.) Latest Developments
Table 60. Merck & Co., Inc. (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 61. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 62. Merck & Co., Inc. (U.S.) Main Business
Table 63. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Merck & Co., Inc. (U.S.) Latest Developments
Table 65. Bristol-Myers Squibb Company (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 66. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 67. Bristol-Myers Squibb Company (U.S.) Main Business
Table 68. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Bristol-Myers Squibb Company (U.S.) Latest Developments
Table 70. Boehringer Ingelheim GmbH (Germany) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 71. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 72. Boehringer Ingelheim GmbH (Germany) Main Business
Table 73. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Boehringer Ingelheim GmbH (Germany) Latest Developments
Table 75. Genentech, Inc. (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 76. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 77. Genentech, Inc. (U.S.) Main Business
Table 78. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Genentech, Inc. (U.S.) Latest Developments
Table 80. Cipla, Inc. (India) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 81. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 82. Cipla, Inc. (India) Main Business
Table 83. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. Cipla, Inc. (India) Latest Developments
Table 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Table 3. Major Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Major Players of Entry and Fusion Inhibitors
Table 5. Major Players of Protease Inhibitors (PIs)
Table 6. Major Players of Integrase Inhibitors
Table 7. Major Players of Coreceptor Antagonists
Table 8. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 10. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 11. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 12. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Player (2019-2024)
Table 16. Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Products Offered
Table 17. Human Immunodeficiency Virus (HIV)-1 Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 21. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Regions (2019-2024)
Table 22. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 23. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 24. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 25. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country (2019-2024)
Table 26. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 27. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 28. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 29. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 30. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 31. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Table 32. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 33. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 34. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 35. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 36. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 37. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country (2019-2024)
Table 38. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 39. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 40. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 41. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 42. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Table 44. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 45. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Table 46. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 47. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Table 48. Key Market Drivers & Growth Opportunities of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 49. Key Market Challenges & Risks of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 50. Key Industry Trends of Human Immunodeficiency Virus (HIV)-1 Therapeutics
Table 51. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 52. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 53. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 54. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 55. AbbVie, Inc.(U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 56. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 57. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 58. AbbVie, Inc.(U.S.) Main Business
Table 59. AbbVie, Inc.(U.S.) Latest Developments
Table 60. Merck & Co., Inc. (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 61. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 62. Merck & Co., Inc. (U.S.) Main Business
Table 63. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Merck & Co., Inc. (U.S.) Latest Developments
Table 65. Bristol-Myers Squibb Company (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 66. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 67. Bristol-Myers Squibb Company (U.S.) Main Business
Table 68. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Bristol-Myers Squibb Company (U.S.) Latest Developments
Table 70. Boehringer Ingelheim GmbH (Germany) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 71. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 72. Boehringer Ingelheim GmbH (Germany) Main Business
Table 73. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 74. Boehringer Ingelheim GmbH (Germany) Latest Developments
Table 75. Genentech, Inc. (U.S.) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 76. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 77. Genentech, Inc. (U.S.) Main Business
Table 78. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 79. Genentech, Inc. (U.S.) Latest Developments
Table 80. Cipla, Inc. (India) Details, Company Type, Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served and Its Competitors
Table 81. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offered
Table 82. Cipla, Inc. (India) Main Business
Table 83. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 84. Cipla, Inc. (India) Latest Developments
LIST OF FIGURES
Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type in 2023
Figure 10. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Hospitals
Figure 11. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Clinics
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Labs
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Labs (2019-2024) & ($ Millions)
Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application in 2023
Figure 17. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Value Market Share by Country in 2023
Figure 24. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application in 2023
Figure 31. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Figure 40. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type in 2023
Figure 10. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Hospitals
Figure 11. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Clinics
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Human Immunodeficiency Virus (HIV)-1 Therapeutics in Labs
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Labs (2019-2024) & ($ Millions)
Figure 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application in 2023
Figure 17. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Value Market Share by Country in 2023
Figure 24. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application in 2023
Figure 31. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Figure 40. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Market Share Forecast by Application (2025-2030)
